Genmab (GMAB)
(Delayed Data from NSDQ)
$28.24 USD
-0.11 (-0.39%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $28.24 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
GMAB 28.24 -0.11(-0.39%)
Will GMAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GMAB
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Other News for GMAB
What 8 Analyst Ratings Have To Say About Genmab
J&J wins another FDA label expansion for multiple myeloma therapy
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Genmab (GMAB) and Penumbra (PEN)
Strong Buy Rating for Genmab’s Stock Backed by FDA Approval and Positive Clinical Data
Baird Q2 2024 International And Global Growth Fund Commentary